Endeavor notches major mid-stage trial win, says IPF drug can reverse disease

Endeavor BioMedicines' taladegib meets primary endpoint in phase 2b trial for idiopathic pulmonary fibrosis

Endeavor BioMedicines announced that its WHISTLE-PF phase 2b trial of taladegib met its primary endpoint, demonstrating statistically significant improvement in lung function (ppFVC) compared to placebo in patients with IPF. The company claims the drug has potential to reverse disease course, unlike current therapies that only slow progression.